Takeda and Cardurion Pharmaceuticals announce cardiovascular partnership

Takeda has announced a new partnership with Cardurion Pharmaceuticals that will see the companies working to develop novel next-generation therapeutics to treat heart disease.

The cardiovascular development partnership with Cardurion – a recently-launched Boston-based biotechnology company – will see Takeda jumpstart the new company's discovery efforts by providing a 12-person cardiovascular research team from its site in Shonan, Japan.

This will include access to a fully-equipped laboratory space, development resources and licences to a portfolio of preclinical-stage cardiovascular drug programmes.

Dr Andrew Plump, chief medical and scientific officer at Takeda, said: "The creation of this partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists into entrepreneurial environments."

Cardiovascular disease is the leading cause of death worldwide in both men and women, accounting for more than 17 million deaths per year. This figure is expected to rise to nearly 24 million by 2030, meaning there is a strong demand for new therapeutic options.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.